

https://dspace.org/

Oestrogen receptor mutations and their influence on breast cancer growth

Amoils, Karin Dagmar

2012-03-12
http://hdl.handle.net/10539/11415

Downloaded from a DSpace repository. https://dspace.org/

REFERENCES

Aakvaag A., Utaaker E., Thorsen T., Lea O.A. and Lahoot G. Growth and Lahoot
human mammary cancer-7 cells (MCF) in culture: effect of estra
growth factors-containing medium. Cancer Res. 50: 7806-7810, 1990.

Ali S. and Coombs C.R. Endocrine-responsive breast cancer and strate
combating resistance. Nat. Rev. Cancer 2: 101-112, 2002.

Allred D.C., Clark G.M., Tandon A.K., Molina R., Tormey
Gilchrist K.W., Mansour E.G., Abeloff M.D., Guire W.L., Lee-Huang
in node-negative breast cancer: prognostic significance o
influenced by the presence of n.C. in sera of J. Clin. Oncol. 10: 596-605, 1992.

Allred D.C., Mohsin S.K. and Fuqua S.A.W. Histological and
human premalignant breast disease. Endocrine-Related Cancer 8: 467-471, 2001.

Alroy I. and Yarden Y. The ErbB signalling network in
oncogenesis: signal diversification through combinatorial
interactions. FEBS Lett. 410: 83-86, 1997.

Al Saati T., Clamens-Kna, Cohen-Faye J.C., Prats H., Coin
Wafflart J., Ère Pri, Bayard F. and Delsol G. Production o
antibodies to human estrogen receptor protein (ER) usin
(RER). Int. J. Cancer 55: 656-654, 1993.

Anders C.K., Hsu D.S., Broadwater G., Acharya C.R., Foe
Wang Y., Marcom P.K., Marks J.R., Febbo P.G., Nevins
Blackwell Y.L. Young age at diagnosis correlates with worse
defines a subset of breast cancers with shared patterns of
Clin. Oncol. 26: 3324-3330, 2008.

Anderson E. The role of oestrogen and progesterone re
mammary development and tumorigenesis. Breast Cancer. 4: 197-201, 2002.

Archey W.B., McEachern K.A., Robson M., Offit K., Vaziri S
and Arrick B.A. Increased CpG methylation of the estrog
BRCA-linked estrogen-receptor-negative breast cancer. Oncogene 21: 7034-
7041, 2002.

Arnold A., Cossman J., Bakhshi A., Jaffe E.S., Waldmann T.A.
S.J. Immunoglobin gene rearrangements as unique clonal
lymphoid neoplasms. N. Engl. J. Med. 309: 1593-1599, 1983.

Bakas P., Liapis A., Vlahopoulos S., Grinatsas M., Logothetis S.
A.K., Alexis M.N. and Zoumpourlis V. Estrogen receptor ± and ² in uterine
a basis for altered estrogen-response in Fertility and Sterility 89: 1788-1795,
2008.

Balakrishnan A., Yang J., Beattie C.W., Gupta T.K.D. and Nand
receptor in dissociated and cultured fibroadenoma epithelial
Cancer Lett. 34 233-242, 1987.

Balslev I., Christensen I.J., Rasmussen B.B., Larsen J.
Thorpe S.M., Rose C., Briand P. and Mouridsen H.T. Flow
defines patients with poor prognosis in node-negative breast
56 1-6, 1994.

Barlogie B., Drewinko B., Schumann J., Gohde W., Dosik G
D. and Freireich E. Cellular DNA content as a marker of ne
Med. 69 195-203, 1098

Baselga J., Seidman A.D., Rosen P.P. and Norton L. HER2
paclitaxel sensitivity in breast cancer: an
48, 1997.

Baselga J., Perez E.A., Pandiella A. and Rubin S. Adjuvant Trastuzumab:
milestone in the treatment of HER-2-positive early breast cancer.
11: 4-12, 2006.

Beato M. Gene regulation by steroid hormones. Cell 56 335-344, 1989.

Beato M., Herrlich P. and Schutz G. Steroid hormone rece
search of a cell. 83 851-857, 1995.

Beatson G.T. On the treatment of inoperable cases of carc
suggestions for a new method of treatment with illustrative
Lancet 2: 104-107, 1896.

Beekman J.M., Allan G.F., Tsai S.Y., Tsai M.J. and O'Malley Transcriptional
activation by the estrogen receptor requires a conformation
binding domain. Mol. Endocrinol. 7: 1266-1274, 1993.

Beerman H., Kluin P.M., Hermans J., van De Velde C.J.H.
Prognostic significance of DNA ploidy in a series of 690 primary brea
patients. Int. J. Cancer 45: 349, 1990.

Bertelli G., Garmendia O., Mercanoni M., Occelli M., Bertolotti L., Castiglion
F., Fusco O., Del Mastro L. and Leonard R.C. Sequent
exemestane and non-steroidal aromatase inhibitors in advanced b
Oncology 69: 474-477, 2005.

Berthois Y., Katzenellenbogen J.A. and Katzenellenbogen
tissue culture media is a weak estrogen: implications co
estrogen responsive cells in culture. Proc. Natl. Acad. Sci. 83: 2496-2500,
1986.

Blenkiron C., Goldstein L.D., Thorne N.P., Spiteri I., Chi
Barbosa Morais N.L., Teschendorff A.E., Green A.R., Ellis
C. and Miska E.A. MicroRNA expression profiling of huma

identifies new markers of Genome Biol. 2: 14, 2007.

Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., A
Paladini G., Mesiti M., Romeo D., Rinaldini M., Ben
C., Restuccia N., Buzzi F., Franchi R., Massidda B., Dista
Sismondi P. Switching to anastrozole versus continued tamoxi
early breast cancer: Preliminary results of the Italian Trial
J. Clin. Oncol. 23: 5147, 2005.

Bonneterre J., Thürlimann B., Robertson J.F., Krzakows
Koralewski P., Vergote I., Webster A., Steinberg M. and Vo
versus tamoxifen-line therapy advanced breast cancer in
postmenopausal women: results of the Tamoxifen or Arimide
Efficacy and Tolerability Clinical Trial. 18: 3757, 2000.

Bowler J., Lilley T.J., Pittam J.D. and Wakeling A.E. N
antiestrogenic Steroids 54: 7-19, 1989.

Boyd M., Hildebrandt R.H. and Bartow S.A. Expression of
gene in developing and adult human breast. Res. 37: 248.
251, 1996.

Bronson F.H., Dagg C.P. and Snell G.D. Biology of the laboratory mouse
Reproduction 18: 7, 1975.

Bronzert D.A., Greene G.L. and Lippman M.E. Selection and breast cancer cell line resistant to the Endocrinology 117 Endocrinology LY 117 1409-1417, 1985.

Brooks S.C., Locke E.R. and Ruler H.D. Estrogen receptor in a human ce (MCF-7) from breast carcinoma. Cancer Res. 28 6251-6253, 1973.

Brueggemeier R.W., Hackett J.C. and Diaz-Cruz E.S. Aromatase Inhibitors in t Treatment of Breast Cancer. Rev. 33 145, 2005.

Brunner N., Clarke R., Lippman M.E. and Dickson R.B. Mo progression from-dependent to-independent growth in hum breast cancer. In Growth Regulation of Cancer. Lippman M.E., Dickson R. (eds). Alans R. Liss, Inc. Yorkpp 1 9 0 115.

Bryant W., Snow E., Rice L.W. and Shupnik M.A. Thenestrogen receptor (E ± variant "5 exhibits dominant positive activity on ER in endometrial carcinoma. Endocrinology 146 7515, 2005.

Buzdar A.U., Marcus C., Holmes F., Hug V. and Hortobagyi of Lyi 56758 in metastatic breast cancer. Oncology 45 3443-445, 1988.

Buzdar A. and Howell A. Advances in aromatase inhibition tolerability in the treatment of breast cancer. Clin. Cancer Res. 7 (Pt) 2 2635, 2001.

Cairns J. Mutation, selection and the natural history of cancer. Nature (London) 255: 197-200, 1975.

Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch Shimizu M., Rattan S., Bullrich F., Negrini M. and Croce C genes are frequently at fragile sites and genomic regions cancers. Proc. Natl. Acad. Sci. USA 101: 2999-3004, 2004.

Calin G.A. and Croce C.M. MicroRNA signatures in human Cancer. Nat. Rev. 6: 857-866, 2006.

Cameron G. and Chambers R. Neoplasm Studies of cells human tumours in tissue culture. Am. J. Cancer 1: 1-29, 1937.

Campbell-Thompson M., Lynch J. and Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ER² isoforms in colorectal cancer. Cancer Research 61: 632-640, 2001.

Camplejohn R.S., Ash C.M., Rakunda C., Barnes D.M., Gregor W.M., Richards M.A. and Wilbrook R. The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treat J. Cancer 71: 1-1045, 1995.

Carrel A. On the permanent life of tissues outside the orga
Jr Exp. Med. 15
516-528, 1912.

Carruba G. Estrogen and prostate cancer: an eclipsed truth in an
dominated scenario. J Cell. Biochem. 102: 899-911, 2007.

Carter A.C. Diethylstilbestrol: recommended dosages for
breast cancer patients. JAMA 237: 2079-2085, 1977.

Castles C.G., Fuqua S.A.W., Klotz D.M. and Hill S.M. Expres
constitutively active estrogen receptor variant in the estr
BT-20 human breast cancer cell lines. Cancer Res. 53: 5934-5939, 1993.

Cepa M., Tavares da Silva E., Correia da Silva G., Rocha F. and Teixeira N.
Structure-activity relationships of new A-ring modified steroids as arom
inhibitors. Design, synthesis and biological activity. J. Med. Chem. 48: 6379-6385, 2005.

Cepa M., Correia da Silva G., Tavares da Silva E., Rocha F.M.F., Borges
and Teixeira N.A. New steroidal aromatase inhibitors: sup
dependent breast cancer cell proliferation and induction o
BMC Cell Biol. 9: 4-14, 2008.

Chalbos D., Vignon F., Keydar I. and Rochefort H. Estrogens stimulate proliferation and induce secretory proteins in a human b (T47D). J. Clin. Endocrinol. Metab. 55: 2-6, 1982.

Chambraud B., Berry M., Redeuilh G. Chambon P. and Ba regions of human estrogen receptor are involved in the formation shock protein 90 complex. J. Biol. Chem. 33: 20686-20691, 1990.

Chang E.C., Frasor J., Komm B. and Katzenellenbogen B.S receptor ² on gene networks by gestro receptor ± in breast ca cells. Endocrinology 147: 4831-4842, 2006.

Chappell S.A., Johnson S.M., Shaw J.A. and Walker R.A. Ex receptor alpha variants in non-breast and early invasive carcinomas. J. Pathol. 192: 159-165, 2000.

Cheng A.M., Byrom M.W., Shelton J., Ford L.P. Antisense miRNAs and indicators for an involvement of miRNA in cell Nucleic Acids Res. 33: 1290-1297, 2005

Cheng G., Li Y., Omoto Y., Wang Y., Berg T., Nord M., Vihko P., Warner M Y-S. and Gustafsson J. Differential regulation of estrogen receptor {alpha} and ER {beta} in primate mammary glands. J. Clin. Endocrinol. Metab. 90: 4354-4, 2005

Chetrite G.S., Pasqualini J.R., Pasqualini C., Philippe J., Wright F. and Pasqualini J.C. Comparison of estrogen concentrations, estrone sulfatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol. 72: 23-27, 2000.

Chung Y.L., Sheu M.L., Yang S.C., Lin C.H., Yen S.H. Resistance to tamoxifen-induced apoptosis is associated with direct interaction of her-2/neu and cell membrane estrogen receptor-alpha in breast cancer. Int. J. Cancer 96: 306-312, 2002.

Clark G.M., McGuire W.L., Hubay C.A., Pearson O.H., Marshall J.S. and Levitt S.H. Progesterone receptors as a prognostic factor in stage II breast cancer. N. Engl. J. Med. 309: 1343-1347, 1983.

Clark G.M., Osborne C.K. and McGuire W.L. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol. 2: 1101-1109, 1984.

Clark G.M. and McGuire W.L. Steroid receptors and other prognostic factors in primary breast cancers. Semin. Oncol. 15: 12-20, 1988.

Clarke R., Dickson R.B. and Brunner N. The progression from breast hyperplasia to human breast cancer. Ann. Oncol. 1: 401-407, 1990.

Clemens J.A., Bennett D.R., Black L.J. and Jones C.D. antiestrogen, keoxifene (LY156758), on-induced mammary tumors and on LH and prolactin. Science 3:1286-1289, 1983.

Cocconi G. First generation aromatase inhibitors and testololactone. Breast Cancer Res. 5-80, 1994.

Cohen B.D., Siegall C.B., Bacus S.S., Foy J.M., Hellstrom I., H K.E. and Fell H.P. Role of epidermal growth factor receptor fami growth and differentiation of breast carcinoma. Sympo 6:1-10, 1998.

Cole M.P., Jones C.T.A. and Todd-Ostrog A. Anti-oestrogen in a breast cancer. Br. J. Cancer 25-275, 1971.

Cooke T., George D., Shields R., Maynard P.V. and Gri receptors and prognosis in early breast cancer. Lancet 1:959-1979.

Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem S.E., Alvarez I., Bertelli G., Ortmann O., Coates A.S., B Coleman R.E., Fallowfield L.J., Mickiewicz E., Andersen J. G., Stewart A., Stuart N., Snowdon C.F., Carpentieri M., J.M. A randomized trial of exemestane after two to three yea therapy in postmenopausal women with primary breast can. N. Engl. J. Med. 350:1081-1092, 2004.

Cooper A.: The principles and practice of surgery, vol. 1. London: pp 335, 1836.

Coulson P.B., Thornthwaite J.T., Woolley T.W., Sugarbaker Prognostic indicators including DNA histogram type, recept related to human breast cancer. Cancer Res. 44: 4187-4196, 1984.

Cowley S.M., Hoare S., Mosselman S. and Parker M.G. Estrog ðb form heterodimers. J. Biol. Chem. 272: 19858-19862, 1997.

Crandall D.L., Busler D.E., Novak T.J., Weber R.V. and Kr estrogen receptor ² RNA in human breast and abdominal su tissue. Biochem. Biophys. Res. Commun. 248: 532-536, 1998.

Critchley H.O., Henderson T.A., Kelly R.W., Scobie G.S., N.P. and Saunders P.T. Wild-type estrogen receptor (ER²1) and the splice v (ER²cx/²2) are both expressed within the human endometr normal menstrual cycle. J. Clin. Endocrinol. Metab. 87: 5265-5273, 2002.

Cui X., Schiff R., Arpino G., Osborne C.K. and Lee A.V. B Receptor Loss in Breast Cancer and Its Implications for E Clin. Oncol. 23(30): 7721-7735, 2005.

Daffada A.A., Johnston S.R., Smith I.E., Detre S., King N. deletion variant estrogen receptor mRNA expression in relation tamoxifen resistance and progesterone receptor/pS2 stat cancer. Cancer Res. 55: 2828-2833, 1995.

De Sombre E.R., Carbone P.P., Jensen E.V., McGuire W.L., J.L. and Lipsett M.B. Steroid receptors in breast cancer. Surg. Gynecol. Obstet. 148: 1001-1012, 1979.

Desai A.J., Luqmani Y.A., Walters J.E., Coope R.C., Dagg P.E., Rees C.N., Thirunavukkarasu V., Shousha S., Groom and Ali S. Presence of deleted oestrogen receptor in human breast functional analysis and clinical significance. Br. J. Cancer 75: 1177-1184, 1997.

De Vivo I., Hankinson S.E., Colditz G.A., Hunter D.J. polymorphism in the progesterone gene is associated with cancer risk. Cancer Res. 63: 5235-5238, 2003.

Dobrzycka, K.M., Townson S.M., Jiang S., Oesterreich S. corepressors: A role in human breast cancer? Endocr. Relat. Cancer 10: 517-536, 2003.

Dodds E.C. and Lawson W. Synthetic estrogenic agents without a ph nucleus. Nature (Lond.) 137: 996, 1936.

Don R.H., Cox P.T., Wainwright B.J., Baker K. and Mattick
to circumvent spurious priming during gene amplification. Nucleic Acids Res.
4008, 199

Dotzlaw H., Alkhalaf M. and Murphy L.C. Characterization
variant mRNAs from human breast cancers. Mol. Endocrinol. 6: 773-785, 1992.

Dotzlaw H., Leygue E., Watson P.H. and Murphy L.C. Exp
receptor beta in human breast tumors. J. Clin. Endocrinol. Metab. 82: 2371-2374,
1997.

Dotzlaw H., Leygue E., Watson P.H. and Murphy L.C. E
messenger RNA expression in human breast tumor biops
steroid receptor status and regulation by tamoxifen. Cancer Res. 59: 2925-2932,
1999.

Dupont S., Krust A., Gansmuller A., Dierich A., Chambon P
single and compound knockouts of estrogen receptors alp
(ER²) on mouse reproductive phenotypes. Development 127: 4277-4291, 2000

Dupont W.D. and Page D.L. Risk factors for breast can
proliferative breast disease. N. Engl. J. Med. 312: 146-151, 1985.

Duval D., Duran D. and Homebarche F. Genomic effects of steroi
Interactions of steroid with membrane structures and fu
Biochim. Biophys. Acta 737: 404-42, 1983.

Earle W.R., Schilling E.L., Stark T.H., Straus N.P., Brown
Production of malignancy in vitro. The mouse fibroblast cultures and
seen in the living cells. Natl. Cancer Inst. 4: 165-12, 1943.

Elledge R.M., Green S., Pugh R.C., Allred D.C., Clark G.M., Hill J., R
Martino S. and Osborne C.K. Estrogen receptor (ER) and p
(PgR), by ligand-binding assay compared with ER, PgR and pS2, by immun
histochemistry in predicting response to tamoxifen in metastatic
Southwest Oncology Group Study 8 (2): 1-117, 2000.

Ellis L., Atadja P.W. and Johnstone R.W. Epigenetics i
chromatin modifications. Mol. Cancer Ther. 8: 1409-1420, 2009.

Encarnacion C.A., Ciocca D.R., McGuire W.L., Clark G.M.
Osborne C.K. Measurement of steroid hormone receptors
patients on tamoxifen. Breast Cancer Res. 26: 2374-6, 1993.

Engel L.W. and Young N.A. Human breast carcinoma in continuous cultu
review. Cancer Res. 38: 4327-4339, 1978.

Enmark E., Pelto-Huikko M., Grandien K., Lagercrantz S., Lagercr
Nordenskjold M. and Gustafsson J.A. Human estrogen receptor gene structure,
chromosomal localization, and expression patterns. J. Clin. Endocrinol. Metab.
4254-4265, 1997.

Erenburg I., Schachter B., Mira y Lopez R. and Ossowski L
receptor isoform (ERe3) in breast cancer and the consequences
reexpression: interference-with estrogen-stimulated properties of malig
transformation. Mol. Endocrinol. 11:2004-2015, 1997.

Esber H., Payne I. and Bogden A. Variability of hormone co
in commercial sera used for tissue culture. J. Nat. Cancer Inst. 50:1956-1962, 1973.

Faber L.E., Sandmann M.L. and Stavely H.E. Progesterone
rat and rabbit uterus. J. Biol. Chem. 247:5648-5649, 1978.

Fan S., Wang J., Yuan R., Ma Y., Meng Q., Erdos M.R., Pestell R.G.,
Auborn K.J., Goldberg I.D. and Rosen E.M. BRCA1 inhibition of estrogen re
signalling in transfected cells. Science 284:1354-1356, 1999.

Fasco M.J., Hurteau G.J. and Spivack S.D. Gender-dependent expression of
alpha and beta estrogen receptors in human nontumor and t
Endocrinol. 188:1215-1240, 2002

Ferguson A.T. and Davidson N.E. Estrogen Receptor ± Func
Breast Cancer. Crit. Rev. in Oncogenesis 8: 2-4, 1997.

Fernandez P., Wilson C., Hoivik D. and Safe S.H. A
characteristics of T47d human breast cancer cells after
estrogen-deficient medium. Cell. Biol. Int. 22: 626-633, 1998.

Fernö M., Baldetorp B., Olsson H., Sigurdsson H. and Killand
cytometric DNA index and S-phase fraction in breast cancer in relat
prognostic variables and to clinical outcome. Acta Oncol. 31: 1-5, 1992.

Fialkow P. Clonal origin of human tumors. Annu. Rev. Med. 30: 135-143, 1979.

Filipowicz W., Bhattacharyya S.N. and Sonenberg N. Mo
transcriptional regulation by microRNAs: are the answers
Nat. Rev. Genet. 9: 102-114, 2008.

Fisher B., Gunduz N., Constantino J., Fisher E.R., Redmon
and Siderits R. DNA flow cytometric analysis of primary operable breast
Cancer (Phila.) 68: 1465-1475, 1991.

Fisher B., Constantino J.P., Wickerham D.L., Redmond C.K., Kavanah M.
W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Chiu Daly M
E., Ford L. and Wolmark N. Tamoxifen for prevention of breast cance

the National Surgical Adjuvant Breast-and Bowel Project. Cancer Inst 90: 1371-1388, 1998.

Fisher B. From Halsted to prevention and beyond: advance of breast cancer during the twentieth century. Eur J Cancer 35: 1961-1973, 1999.

Fitzpatrick S.L., La Chance M.P.G., Schultz G.S. and Characterization of e growth factor receptor and action on human breast cancer. Cancer Res 44: 3443-3447, 1984.

Focan C., Beauduin M., Majoul F., Cusumano G., Focan H., and Lobelle J.P.: Adjuvant Cancer Project, Belgium. High-dose oral medroxyprogesterone acetate or tamoxifen as adjuvant horm negative-early breast cancer: randomized-trial with 7-year updating. Breast Cancer 5: 1361-1641, 2004.

Foulds L. Neoplasm Development, Vol. 2. New York: Academic Pr

Fu X.D., Giretti M.S., Goglia L., Flamini M.I., Sanchez A.M., S., Sitruk-Ware R., Genazzani A.R. and Simoncini T. Compar progesterone, medroxyprogesterone, dromes, acetone and nestoron breast cancer cell migration. Mol Cancer 8: 1667-1678, 2008.

Fujimura T., Takahashi S., Urano T., Ogawa S., Muramatsu T., K M. and Inoue S. Differential expression of estrogen receptor beta (ER-beta) and its

C-terminal truncated splice variant ERbetacx as prognostic
prostatic cancer. Biochem. Biophys. Res. Commun. 289:6 6299, 2001

Fuqua S.A., Fitzgerald S.D., Chamness G.C., Tandon A.K
Nawaz Z., O Malley B.W. and McGuire W.L. Variant human breast t
receptor with constitutive transcriptional activity. Cancer Res. 1 1:5 0 9, 1991.

Fuqua S.A., Fitzgerald S.D., Allred D.C., Elledge R.M., Nav
O Malley B.W., Greene G.L. and McGuire W.L. Inhibition of estrogen
action by a naturally occurring variant in human breast cancers. Res. 52:
483-486, 1992.

Fuqua S.A., Allred D.C. and Auchus R.J. Expression of estr
J. Cell Biochem. Suppl. 17 1994, 1971, 1993.

Fuqua S., Wiltschke C., Castles C.G., Wolf D.C. and All
estrogen receptor variants in endocrine resistance. Endocr. Res. 2 1:2 5, 1995.

Fuqua S.A.W., Wiltschke C., Zhang Q.X., Castles C.G., Friedrichs W
Hopp T., Hilsenbeck S., Mohsin S., O Connel P. and Allred
estrogen receptor-mutation in premalignant breast cancer. Cancer Res. 60:
402-4029, 2000.

Fuqua S., Schiff R., Parra I., Moore J.T., Mohsin S., Osborn M. and Allred D.C. Estrogen receptor ² protein in human breast cancer clinical tumor parameters. Cancer Res. 63: 2434-2439, 2003.

Furberg S., Veiden M.B., Wilsgaard T., Bernstein L. and Thune-density lipoprotein cholesterol, metabolic profile, and breast cancer. J. Nat. Cancer Inst. 96: 1151-1160, 2004.

Garcia Pedrero J.M., Zuazua P., Martinez-Campa C., Lazo P.S. and Ramo The naturally occurring variant of estrogen receptor (ER estrogen-dependent transcriptional activation by ER-both wild-type ER². Endocrinology 144: 2967-2976, 2003.

Garinis G.A., Patrinos G.P., Spanakis N.E. and Meno hypermethylation: when tumour suppressor genes go silen Hum. Genet. 111: 115-127, 2002.

Gaub M.P., Bellard M., Sheuer I., Chambon P. and Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor in Cell. Cell. 63: 1267-1276, 1990.

Gazic B., Pizem J., Bracko M., Cufer T., Bosnar Z., Poha-Marinovskaya U., Krasovec M. Phase fraction determined on fine needle asp independent prognostic factor in a multivariate study of 7 patients. Cytopathology 19: 2934-2402, 2008.

German J. (ed.). Chromosome Mutation and Neoplasia. Alan R. Liss, New
1983.

Gey G.O., Coffman W.D. and Kubicek M.T. Tissue cultu
proliferative capacity of cervical carcinoma and normal ep
Cancer Res. 12 363-365, 1952.

Ghate R.P., Jacobsen B.M., Schittone S.A. and Horwitz K.B. The progestrone
and androgenic properties of medroxyprogesterone aceta
overlap with dihydrotestosterone in breast cancer. Cancer Res. 7 Rels.
R1036-R1050, 2005.

Giacinti L., Claudio P.P., Lopez M. and Giordano A. Epige
estrogen receptor alpha expression in breast cancer. Oncologist 11, 2006.

Glauber J.G. and King D.T. The changing role of hormonal
breast cancer. Semin. Oncol. 19 303-316, 1992.

Glover J.F., Irwin J.T. and Parker D. Interaction of phenol
estrogenic and antiestrogenic action on growth of human b
751 and 47-D. Cancer Res. 48 3693-3697, 1988.

Gooch J.L. and Yeaman S. Specific differences in formation of apo
ladders in MCF-7 breast cancer cells. Lett. 143-137, 1999.

Graham M.L. II., Dalquist K.E. and Horwitz K.B. Simultan
progesterone receptors and DNA indices by flow cytometry
cancer cell mixtures and ability of the T47D cancer Res.
3943-3949, 1989.

Graham M.L., Krett N.L., Miller L.A., Leslie K.K., Gordon
L.L. and Horwitz K.B. T47D cells, genetically unstable and containi
receptor mutations, are a progression of breast cancers to
resistance. Cancer Res. 6208-6217, 1990.

Green S., Walter P., Kumar V., Krust A., Bornert J.M., Arg
Human oestrogen receptor cDNA: sequence, expression and
Nature (London) 320 134-139, 1986.

Green S. and Chambon P. Oestradiol induction of a glucocorticoid-responsive
gene by a chimaeric receptor. Nature 325 75-78, 1987.

Greene G.L., Nolan C., Engler J.P. and Jensen E.V. Monoc
human estrogen receptor. Proc. Natl. Acad. Sci. USA 77 5115-5119, 1980.

Greene G.L. and Jensen E.V. Monoclonal antibodies as p
receptor detection and characterization. J. Steroid Biochem. 16 353-359, 1982.

Greene G.L., Gilna P., Waterfield M., Baker A., Hort Y. and Shine J. Sequ
and expression of human oestrogen receptor complement Science
(Washington D.C.) 2 1 1 1 5 0 1 5 4, 1986.

Gross G.E., Clark G.M., Chamness G.C. and McGuire W.L. Multiple progesterone
receptor assays in human breast cancer cells. Cancer Res. 4 4 8 3 6 4 0, 1984.

Gullick W.J. and Srinivasan R. The type 1 growth factor
ligands and receptors and their role in breast cancer. Recent Trea
52 4 5 3, 1998.

Haddow A., Watkinson J.M. and Paterson E. Influence of synthetic oestro
upon advanced malignant disease. Brit. Med. 2 3 9 3 9 8, 1944.

Han F., Miksicek R., Clarke R. and Conrad S.E. Express
receptor variant lacking exon 3 in 7 derivatives of MCF-
estrogen independence or tamoxifen resistance. J. Mol. Endocrinol. 32 9 3 5.
945, 2004.

Harrison R.G. Observations on the living developing nerve. Proc. Soc. Exp.
Biol. Med. 4 1 1 0 4 3, 1907.

Hemsell D.L., Grodin J., Brenner P.F., Siiteri P.K. and Ma
precursors of estrogen. II. Correlation of the extent of

androstenedione to estrone with Endocrinol. Metab. J. Clin. Endocrinol. 38: 474-479, 1974.

Henderson B.E., Ross R.K., Pike M.C. and Casagrande hormones as major factor in human cancer. Research 42: 232-239, 1982.

Henderson B.E., Ross R. and Bernstein L. Estrogens as cancer: the Richard and Hilda Rosenthal Foundation Award le Cancer News 48: 2-6, 1988.

Henderson I.C. Cure therapy in metastatic breast cancer In Breast Diseases. Harris J.R., Hellman S., Henderson I.C and Kinne Lippincott Co., Philadelphia, 1987. 428, 1987.

Henry J.A., Nicholson S., Farndon J.R., Westley B.R. and Mayn E.M. of oestrogen mRNA levels in human breast cancer. Br. J. Cancer 58: 606-605, 1988.

Herynk M.H. and Fuqua S.A. Estrogen receptor mutations Endocr. Rev. 25: 868-898, 2004.

Herynk M.H. and Fuqua S.A. Estrogen receptor mutations in resi therapy. Adv. Exp. Med. Biol. 608: 1-1043, 2007.

Holbro T., Civenni G. and Hynes N.E. The ErbB receptors a
progression. Exp. Cell Res. 284: 99-110, 2003.

Hopp T.A., Weiss H.L., Hilsenbeck S.G., Gunby, Allred, D.C., B. and Horwitz K.
Fuqua S.A. Breast cancer patients with progesterone receptor
have poorer disease-free survival rates. Clin. Cancer Res. 10: 2751-2760, 2004.

Horvath G., Lesha G., Hanlin M. and Henriksson M. Exon deletions and variant
human rogten receptor mRNA in endometrial hyperplasia and
Int. J. Gynecol. Cancer 10: 1233-1236, 2000.

Horwitz K.B., McGuire W.L., Pearson O.H. and Segaloff A.
to endocrine therapy in human breast cancer: a hypothesis. Science 189: 726-727, 1975.

Horwitz K.B., Costlow M.E. and McGuire W.L. MCF-7 cancer c
line with estrogen, androgen, progesterone and glucocortic Steroids
26: 785-795, 1975.

Horwitz K.B and McGuire W.L. Estrogen control of progesterone receptor in
human breast cancer. J. Biol. Chem. 253: 2223-2228, 1978.

Horwitz K.B., Mockus M.B. and Lessey B.A. Variant T47D
cells with high progesterone receptor levels despite estro
resistance. Cell 28: 633-642, 1982.

Howell A., Barnes D.M., Harland R.N., Redford J., Blamwell, V.W., Wilkinson M.J., Swindell R., Crowther D. and Sterlwood R.A. Serum oxytocin receptors and survival after relapse in breast cancer. Lancet 17: 585-591, 1984.

Huang Q., Gumireddy K., Schrier M., le Sage C., Nagel R., Nair S. A., Huang G.-Szalnin A.J., Gimotty P.A., Katsaros D., Coukos Puré E. and Agami R. The microRNA-373 and -520c promote tumour invasion and metastasis. Nat. Cell Biol. 10: 202-210, 2008.

Huggins C. and Hodges C.V. Studies on prostatic cancer castration, of estrogen and of androgen injection on serum metastatic carcinoma of the prostate. Cancer Res. 2: 297, 1941.

Hutcheson I.R., Knowlden J.M., Madden T.A., Barrow D.J., Wakeling A.E. and Nicholson R.I. Oestrogen-mediated modulation of the EGFR pathway in tamoxifen-resistant MCF-7 breast cancer. Res. 81: 8-93, 2003.

Huynh H.T. and Pollack-Kim M. Growth-inhibitor I gene expression uterus is stimulated by tamoxifen and inhibited by the p 18278. Cancer Res. 53: 5585-5588, 1993.

Ingram D., Nottage E., Ng S., Sparrow L., Roberts A. and W breast cancer. Cancer 64: 1049, 1989.

Inoue S., Ogawa S., Horie K., Hoshino S., Goto W., Hos
Muramatsu M. and Ouchi Y. An estrogen receptor ² isoform that lacks
dominant negative activity on both Ecke and Ep². Biochem. Biophys. Res
Commun. 279 8-14 19, 2000.

Iorio M.V., Ferracin M., Liu C.G., Veronese A., Magri S., Spizzo R.,
Pedriali M., Fabbri M., Miglio Menard, Palazzo J., Rosenberg A.,
Musiani P., Volinia N., Nenci C., Galli A., Querzoli P., Negrini M. and Croce C.M
MicroRNA gene expression deregulation in human breast ca Cancer 67
706-5 7070, 2005.

Iwao K., Miyoshi Y., Egawa C., Ikeda N. and Nogushi S. Quantitati
estrogen re-ceptor ² mRNA and its variants in human breast ca Int. J.
Cancer 88 73-7 36, 2000a.

Iwao K., Miyoshi Y., Egawa C., Ikeda N., Tsukamoto F
Quantitative analysis of re-ceptor ² messenger RNA expression
breast carcinoma by polymerase chain reaction. Cancer 89 17-12 38,
2000b.

Jacquemier J.D., Hassoun J., Torrente M., Distribution of Estrog
and progesterone receptors in the adjacent to breast lesion
stages immunohistochemical study of 107 cases. Breast Cancer Res. 15 Treat.
109 117, 1990.

Jarvinen T.A., Pekko M., Holli K. and Isola J. Estrogen receptor ² is coexpressed with ER± and PR and coexpressed with nodal status, grad proliferation rate in breast cancer. Am. J. Pathol. 156: 2-35, 2000.

Jolly D.J., Okayama H., Berg P., Esty A.C., Filpula D., Bo Shively J.E., Hunkapillar T. and Friedman T. Isolation of an full-length expressible cDNA for human hypoxanthine phosph transferase. Proc. Natl. Acad. Sci. USA 80: 7-4, 1983.

Jones C., Payne J., Wells D., Delhanty J.D., Lakhani S.R Comparative genomic hybridization: extensive variation among MCF-7 cell stocks. Cancer Genet. Cytogenet. 117: 1-15, 2000.

Jordan V.C. Selective estrogen receptor modulation: conce in cancer. Cancer Cell 6: 2-7, 2004.

Jordan V.C. and Dowsett L.J. Tamoxifen as an antimour agent: effect o oestrogen binding. J. Endocrinol. 68: 2-3, 1976.

Jordan V.C., Jacobson H.I. and Kemeinan E. Jo. Determination of estrogen recep breast cancer using monoclonal antibody technology: result in the United States. Cancer Res. 46: 423-428, 1986.

Kalhert S., Nuedling S., van Eickels M., Vetter H., Mey
Estrogen receptor alpha rapidly-activates the IGF-1 receptor pathway. J. Biol.
Chem. 275 18447-18453, 2000.

Karnik S.P., Kulkami S., Liu X.P., Buxton G.T. and Bukowski R.M. E
receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 54 3043-3053,
1994.

Kastner P., Krust A., Turcotte B., Stropp U., Tora L., Gronemeyer H.,
Chambon P. Two distinct estrogen-regulated promoters generate tran
encoding the two functionally different human progesterone
B. EMBO J. 9 1603-1614, 1990.

Katzenellenbogen B.S., Montano M.M., Ekena K., Herman M.E., Mc
E.M. William L. McGuire Memorial Lecture. Antiestrogens: mechanism
and resistance in breast cancer. Breast Cancer Res. Treat. 51 227-238, 1997.

Keeling J.W., Ozer E., King G. and Walker F. Oestrogen re
fetal, infant, and child mammary tissue. J. Pathol. 191 441-451, 2000.

Keydar I., Chen L., Karbey S., Weiss F.R., Delarea J., Ra
Brenner H.J. Establishment and characterization of a cell
carcinoma of the breast. Eur. J. Cancer 15 659-670, 1979.

Khan S.A., Rogers M.A., Obando J.A. and Tamsen A. Estroge
expression of benign breast epithelium and its associatio
Cancer Res. 54: 993-997, 1994.

Kim S. H., Moores J.C., David D., Respess J.G., Jolly D.J.
organization of the human HPRT gene. Nucleic Acids Res. 14: 3103-3118, 1986.

King W.L and Green G.L. Monoclonal antibodies localize es
nuclei of target cells. Nature 307: 293-304, 1984.

Klapper L.N., Kirschbaum M.H., Sela M. and Yarden Y. Biol
implications of the ErbB/HER signalling network. Adv. growth
Cancer Res. 77: 25-79, 2000.

Klein G. Lymphoma development in mice and humans: div
followed by convergent cytogenetic evolution. Proc. Natl. Acad. Sci. USA.
244-2446, 1979.

Klein-Hitpass L., Tsai S.Y., Greene G.L., Clark J.M., Hall, Tsai M.J.
Specific binding of estrogen receptor to the estrogen response
Biol. 9: 43-49, 1989.

Klotz D.M., Castles C.G., Curtis S.A., Spriggs L.L., Hilsenbeck S.M.
expression of wild type and variant ER mRNAs by breast cancers. MCF

cells may account for differences in estrogen responsiveness. Biochem. Biophys. Res. Commun. 210: 606-615, 1995.

Knight W., Livingstone R.B., Gregory E.J. and McGuire W.L. as an independent prognostic factor for early recurrence in Cancer Res. 37: 4669-4671, 1977.

Koehorst S.G., Cox J.J., Donker G.H., Lopes da Silva S., Sinn J.H. and Blankenstein M.A. Functional analysis of an alternative receptor lacking exon 4 isolated from MCF-7 breast cancer cells and menin tissue. Mol. Cell Endocrinol. 104: 125, 1994.

Koenders P.G., Beex L.V., Kloppenborg P.W., Spaulborg A.G. and Benraad T. Human breast cancer: Survival from first metastasis. Breast Breast Cancer Res. 21: 17-30, 1992.

Korenman S.G. Radioligand binding assay of specific estro uterine macromolecule. J. Clin. Endocrinol. 28: 1274-1280, 1968.

Kraus W.L., McInerney E.M. and Katzenellenbogen, B.S. transcriptionally productive association of hormone-dependent cofactor-binding regions of a steroid hormone. Natl. Acad. Sci. USA 92: 12318-12321, 1995.

Kuiper G., Enmark E., Pelto-Huikko M., Nilsson S. and Gustafsson J.A. a novel estrogen receptor expressed in Proc. Natl. Acad. Sci. USA 93: 5925-5930, 1996.

Kuiper G.G.J.M., Carlsson B., Grandien K., Enmark E., Haggblad I., N and Gustafsson J.A. Comparison of the ligand binding specificity tissue distribution of estrogen receptors in Endocrinology 138: 863-870, 1997.

Kumar V., Green S., Stack G., Berry M., Jin Jr. and Chambon P. Functional domains of the human estrogen receptor. Cell 51: 941-951, 1987.

Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R. Webb P. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74: 311-317, 2000.

Kute T.E., Muss H.B., Anderson D., Crumb K., Miller B., B Relationship of steroid receptor, cell kinetics, and clinica breast cancer. Cancer Res. 41: 3524-3529, 1981.

Lacroix M. and Leclercq G. Relevance of breast cancer cell lines as breast tumours: an update. Breast Cancer Res. Treat. 83: 249-289, 2004.

Laidlaw I.J., Clarke R.B., Howell A., Owen O.W.M.C., Pott E. The proliferation of normal human breast tissue, in nud

mice, is stimulated by oestrogen but not by progesterone. Endocrinology 136, 164-171, 1995.

Lake D.E. and Hudis C. Aromatase Inhibitors in Breast Cancer Control 9, 94-98, 2002.

Lakshmanaswamy R., Guzman R.C., Thordarson G., Talamantes F., Yamagni J.R., Nandi S. Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments. Cancer Res. 64, 8231-8237, 2004.

Lasfargues E.Y. and Ozzello L. Cultivation of human mammary carcinoma. J. Natl. Cancer Inst. 21, 1131-1147, 1958.

Lazennec G., Bresson D., Lucas A., Chauveau C., Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142, 4120-4130, 2001.

Leav I., Lau K.M., Adams J.Y., McNeal J.E., Taplin M.E., Wang J., Singh H., Ho S.M. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159, 79-92, 2001

Levenson A.S. and Jordan V.C. Selective oestrogen receptor modulation: molecular pharmacology for the millennium. Eur. J. Cancer 35, 1971-1985, 1999.

Levin ER. Cellular functions of the plasma membrane estrogen
Endocrinol. Metab. 77, 1999.

Levin ER. Cellular functions of plasma membrane estrogen re
67: 471-475, 2002.

Leygue E., Huan Murphy L.C. and Watson P.H. Prevalenc
receptor variant messenger RNAs in human breast cancer.
4327, 1996

Leygue E.R., Watson P.H. and Murphy L.C. Estrogen recep
human mammary tissue. J. Natl. Cancer Inst. 88: 1282-1290, 1996b.

Leygue E., Dotzlaw H., Watson P.H. and Murphy L.C. Altere
and messenger RNA expression during human breast tumo
Res. 58: 3197-3201, 1998.

Lindberg M.K., Moverare S., Skrtic S., Gao H., Dahlman-Wright K., Gustafsson J
Å. And Ohlsson C. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene
transcription, supporting a "Ying Yang" relationship betw
mice. Mol. Endocrinol. 17: 203-208, 2003.

Lindgren P.R., Cajander S., Backman A., Gustafsson J.-Å., Mäkelä S. and
Olofsson J.I. Estrogen and progesterone receptors in ova
Mol. Cell. Endocrinol. 219: 1-7, 2004

Ling V., Chambers A.F., Harris J.F and Hill R.P. Quantitat
tumour progression. Cancer Metastasis Rev. 4: 173-194, 1985.

Lippman M.E. and Bolan G. Oestrogen-responsive human breast cancer i
term tissue culture. Nature (Lond) 256: 592-593, 1975.

Lippman M.E., Bolan G. and Huff K. The effects of estrogens and antiest
hormone responsive human breast cancer in culture. Cancer Res 36: 4595-4601, 1976.

Lippman M.E., Dickson R.B., Gelman E.P., Rosen N., Kn
Bronzert D., Huff K. and Kasid A. Growth regulation of human breas
occurs through regulated growth factor secretion. J. Cell Biochem 35: 1-16, 1987.

Liu M.M., Albanese C., Anderson C.M., Hilty K., Webb P., U
Pestell R.G. and Kuppers P. Opposing action of estrogen receptors
cyclin D1 gene expression. J. Biol. Chem 277: 243-254, 2002.

Lonning P.E. Aromatase inhibitors in breast cancer. Endocrin. Rel. Rev
Cancer 11: 179-189, 2004.

Lonning P.E., Bajetta E., Murray R., Tubiana-Hulin M., Eisenberg P.D., Mick
E., Celio L., Pitt P., Mita M., Aaronson N.K., Fowst C., Ark
Polli A and Massimini G. Activity of exemestane in metastatic breas

failure of nonsteroidal aromatase inhibitors. J. Clin. Oncol. 18: 2334-2340, 2000.

Lowery A.J., Miller N., Devaney A., McNeill R.E., Davoren P.A., Lemetre C., Benes V., Schmidt S., Blake J., Ball G., Kerin M.J.: MicroRNA signature of tumorigenesis predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 11: R27, 2009.

Lu B., Leygue E., Dotzlaw H., Murphy L.J., Murphy L.C.: Estrogen receptor-beta mRNA variants in human and murine tissues. Mol. Cell. Endocrinol. 138: 199-203, 1998.

Mader S., Chambon P. and White J.H.: Defining estrogen receptor binding domain. Nucleic Acids Res. 21: 1249-1258, 1993.

Madsen M.W., Reiter B.E., Larsen S.S., Briand P. and Lykkesfeldt A.E.: Estrogen receptor messenger RNA splice variants are not involved in tamoxifen resistance in sublines of the human breast cancer cell line MCF-7. Cancer Res. 57: 585-589, 1997.

Mann S., Laucirica R., Carlson N., Younes P.S., Ali N., Younes M.: Estrogen receptor ² expression in invasive breast cancer. Hum. Pathol. 32: 113-118, 2001.

Markopoulos C., Berger U., Wilson P., Gazet J.C., Coo
receptor content of normal breast cells and breast carcin
menstrual cycle. Br. Med. J. (Clin. Res. Ed.) 296, 1345-1348, 1988.

Mattie M.D., Benz C.C., Bowers J., Sensinger K., Wong L.,
Ginzinger D., Getts R. and Haqq C. Optimized high throughput microRNA
expression profiling provides novel biomarker assessment of clinical prostate
breast cancer biopsies. Mol. Cancer 5, 24, 2006.

Maynard P.V., Blamey R.W., Elston C.W., Haybittle J.L. and
receptor assay in primary breast cancer and early recurr
Cancer Res. 38, 4294-4295, 1978.

McCormack O., Harrison M., Kerin M.J. and McCann A. Rol
receptor (PR) and the PR isoforms in breast cancer. Crit. Rev. Oncol. Hematol. 63, 293-
302, 2007.

McDonnell D.P., Connor C.E., Wijayaratne A., Chang C.
Definition of the molecular and cellular mechanisms underlying the selective
agonist/antagonist activities of selective estrogen receptor modulators. Recent Prog. Horm. Res. 57, 295-316, 2002.

McEwen B.S., Alves S.E., Bulloch K., Weiland N.G. Ovarian steroids and the
brain: implications for cognition and aging. Neurology 48, S8-15, 1997

McGuire W.L. Steroid hormone receptors in breast cance
Recent Prog. Horm. Res. 36, 155-186, 1980.

McGuire W.L., Carbone P.P., and Sears M.E. Estrogen re
human breast cancer: an overview. In: Estrogen Receptors in Human B
Cancer. McGuire W.L., Carbone P.P. and Vollmer E.P. (eds).
York: pp 1, 1975.

McGuire W.L., Horwitz K.B., Pearson O.H. and Segaloff A. Current status
estrogen and progesterone receptors in breast cancer. Cancer Res. 39: 2934-2943,
1977.

McGuire W.L., Chamness G.C. and Fuqua S.A. Estrogen r
clinical breast cancer. Mol. Endocrinol. 5: 1571-1577, 1991.

McPherson S.J., Ellem S.J. and Risbridger G.P. Estrogen-regulated develop
and differentiation of the prostate gland. Differentiation 76: 660-670, 2008

Merkel D.E., Winchester D.J., Goldschmidt R.A., August C
Rademaker A.W. DNA flow cytometric and morphologic grading as prognosti
in axillary lymph node negative breast cancer. Cancer (Phila.) 71: 2109-2132,
1993.

Miller W.R. Antiaromatase agents: preclinical data and neo
Breast Cancer 1: S-8-S14, 2000.

Miller W.R. and O'Neil J.S. The relevance of local oestrogen meta
breast. Proc. R. Soc. Edinburgh 95B 2031-7, 1989.

Miller W.R., Mullen P., Sourdaine P., Watson C., Dixon
Regulation of aromatase activity within the human. J. Steroid Biochem. Mol. Biol.
61: 192-302, 1997.

Miyoshi Y., Ando A., Shiba E., Taguchi T., Tamaki Y. and N
of up-regulation of 17-hydroxysteroid dehydrogenase type I in ma
intratumoral high estradiol levels in postmenopausal breast cancer. J. Cancer
94: 686-689, 2001.

Montano M.M., Miller V., Trobaugh A. and Katzenellenbogen B.S. The carboxy
terminal F domain of the human estrogen receptor: role
activity of the receptor and the effectiveness as estroge
antagonists. Mol. Endocrinol. 9: 814-825, 1995.

Morris C. and Wakeling A. Fulvestrant (Faslodex) a new treatment option f
patients progressing on prior endocrine therapy. Endocrine Relapsed Cancer 9: 267-
276, 2002.

Mosselman, S., Bolman J. and Dijkema R. Identification an
characterization of a novel human estrogen receptor. FEBS Lett. 392: 49-53,
1996.

Mote P.A., Bartow S., Tran N. and Clarke C. Loss of co
progesterone receptors A and B in breast carcinogenesis
Cancer Res. 72:1-6372, 2002.

Mouridsen H., Gershanovich M., Sun Y., Perez C., Monnier
Apffelstaedt J., Smith R., Sleeboom H.P., Janicke F., Plu
Becquart D., Papsy Salminen E., Snyder R., Lassus M., V
Staffler B., Chaudhri A. and Dugan M. Superior efficacy of letrozole
tamoxifen as first therapy for postmenopausal women with ad
cancer: results of a phase III study of the International Letrozole Breast
Group. J. Clin. Oncol. 19:2596-2606, 2001.

Muddawa L. and Liyanage T. Immunohistochemical asses
receptor status of breast carcinoma: interobserver variati
Indian J. Med. Sci. 63:2-27, 2009.

Murphy L.C., Wang M., Coutt A. and Dotzlaw H. Novel muta
receptor messenger RNA in human breast cancer. J. Clin. Endocrinol. Metab.
1420-1427, 1996.

Murphy L.C., Dotzlaw H., Leygue E., Coutts A. and Wa
pathophysiological role of estrogen receptor variants in hu
Steroid Biochem. Molec. Biol. 65:1-7, 1998.

Murr S.M., Bradford G.E. and Geschwind I.I. Plasma leutin
stimulating hormone and prolactin during pregnancy in the Endocrinology
94: 1211-1216, 1974.

Nabholtz M.J. Long-term safety of aromatase inhibitors in the trea
cancer. Ther. Clin. Risk Manag. 4: 1381-1394, 2008.

Nabholtz J.M., Buzdar A., Pollack M., Harwin W., Burto
Steinberg M., Webster A. and Anastrozole is superior to tamox
first-line therapy for advanced breast cancer in postmenopaus
a North American multicenter randomized trial. J. Clin. Oncol.
Oncol. 18: 3758-3767, 2000.

Narbaitz K., Stumpf W.E. and Sar M. Estrogen receptors
primordia of fetal mouse ovary. J. Embryol. Exp. Morph. 59: 161-166, 1980.

Nathanson I.T. Clinical investigative experience with stero
cancer. Cancer 5: 754-762, 1952.

Nawata H., Bronzert D. and Lippman M.E. Isolation and
tamoxifen resistant cell line derived from a MCF-7 breast cancer cells
Biol. Chem. 256: 5015-5021, 1981.

Nemere I., Pietras R.J and Blackmore P.F. Membrane steroid hormones: Signal transduction and physiological significance. J. Cell. Biochem. Suppl. 38: 438-445, 2003.

Netto G.J., Cheek J.H., Zachariah N.Y., Romer J.C., Lee C. Chakmakjian Z.H. Steroid receptors in benign prostatic tissue. Am. J. Clin. Pathol. 94: 1-7, 1990.

Nicolson G. and Milas L. Cancer Invasion and Metastasis: Therapeutic Aspects (eds.). New York: Raven Press, 1984.

Norris J.D., Fan D., Kerner S. A. and McDonnell D.P. Identification of a second autonomous activation domain within the human estrogen receptor. Mol. Endocrinol. 11: 747-754, 1997.

Nowell P. The clonal evolution of tumor cell populations. Science (Wash. D.C.) 194: 23-28, 1976.

Nowell P. Cytogenetics. In F. Becker (ed.) Cancer: A Comprehensive Treatise, Ed. 2, Vol 1, pp. 1-16. New York: Plenum Publishing Corp., 1982.

Nowell P.C. Mechanisms of tumor progression. Cancer Res. 46: 2203-2207, 1986.

Nugoli M., Chuchana P., Vendrell J., Orsetti B., Ursule L. D., Douzery E., Cohen P. and Theillet C. Genetic variability in MCF-7 sublines: Evidence of rapid genomic and phenotypic changes in breast cancer cell lines. Int. J. Cancer 89: 258-266, 2000.

evidence of rapid genomic and RNA expression. Cancer Biomedicine 3: 13, 2003.

Ogawa S., Inoue S., Watanabe T., Hiroi H., Orimo A., Ho
Muramatsu M. The complete primary structure of human estroge
(hER) and its heterodimerization with ERBi. Biochem Biophys.
Res. Comm. 243: 122-126, 1998a.

Ogawa S., Inoue S., Watanabe T., Orimo A., Hosoi T., Ouc
M. Molecular cloning and characterization of human estrogen
potential inhibitor of estrogen action. Nucleic Acids Res. 26: 3505-3512,
1998b.

Omoto Y., Inoue S., Ogawa S., Toyama T., Yamashita H
Kobayashi S. and Iwase H. Clinical value of the wild-type estrogen receptor
expression in breast cancer. Cancer Lett. 163: 207-212, 2001.

Omoto Y., Kobayashi S., Inoue S., Ogawa S., Toyama T
Muramatsu M., Gustafsson J.A. Evaluation of H. estrogen recep
wild-type and variant protein expression, and relationship w
factors in breast cancer. Eur. J. Cancer 38: 383-386, 2002.

Ormerod M.G. Analysis of DNA in Flow Cytometry: A Practical App
Ormerod M.G. (ed.). RL Press, New York: pp 69, 1990.

Osborne C.K., Yochmowitz M.G., Knight W.A. and McGuire
estrogen and progesterone receptors in the treatment of bre
Cancer 46
2884-2888, 1980.

Osborne C.K., Hobbs K. and Trent J.M. Biological differences among MCF
human breast cancer cell lines from different laboratories.
Breast Cancer Res.
Treat. 9: 111-121, 1987.

Osborne C.K., Jarman M., McCague R., Coronado E.B., H
Wakeling A.E. The importance of tamoxifen metabolism in
breast cancer growth. Chemother. Pharmacol. 34: 895, 1994.

Osborne C. Tamoxifen in the treatment of breast cancer.
N. Engl. J. Med. 339:
1609-1618, 1998.

Ottoviano Y.L., Issa J.P., Parl F.F., Smithvidson B.E., Hayl
Methylation of the estrogen receptor gene CpG island ma
receptor expression in human breast cancer cells.
Cancer Res. 54: 2525-2555,
1994.

Pace P., Taylor J., Suntharalingam S., Coombes R.C. and A
receptor binds DNA in a manner similar to and dimerizes with
J. Biol. Chem. 272: 25832-25838, 1997.

Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J.A., Kushner P.J. and Scanlan T.S. Differential ligand activation of estrogen receptors ERI and ERI AP1 sites. Science (Washington) 277 1508-1510, 1997.

Page M.J., Field J.K., Everett N.P. and Green C.D. Serum estrogen responsiveness of the human breast cancer cell-7. Cancer Res 43 1244-1250, 1983.

Paik S., Bryant J., Park C., Fisher B., Tyrams D., Fisher E., Lippman M.E., Wickerham D.L. and Wolmark N. ERB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone-receptor negative breast cancer. J. Natl. Cancer Inst. 90 (18) 1361-1370, 1998.

Palmieri C., Cheng G.J., Hejima Y., Zelawarri A., Weihua Z., Noorden S., Wahlstrom T., Coombes R.C., Warner M. and Estrogen receptor ² in breast cancer. Endocr. Rel. Cancer 9 113-2002.

Pandey D.P. and Picard D. Inhibits estrogen signalling by direct the estrogen receptor ± mRNA. Mol. Biol. 29 3783-3790, 2009.

Parazzini F., Collina E.M. and Tozzi L. Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal review of published randomized clinical trials. Oncology 50 4-8, 1993.

Park W., Choi J.J., Sho and Lee J. Identification of a variant estro
receptor lacking exon 4 and its co-expression with wild-typ
ovarian carcinomas. Cancer Res. 56: 2290-2295, 1996.

Parshad R., Sanford K.K., Tarone R.E., Jones G.M and B
susceptibility of mouse cells to fluorescent chromosome damag
after long-term culture and malignant transformation. Cancer Res. 39: 2289-2293,
1979.

Patel P.I., Framson P.E., Caskey C.T. and Chinault A.C.
Human Hypoxanthine Phosphoribosyltransferase. Mol. Cell. Biol. 6: 393-403,
1986.

Pedram A., Razandi M., Aitkenhead M., Hughes C.C. and Le
the non-genomic and genomic actions of estrogen: integrated linea
by steroid to transcription. J. Biol. Chem. 277: 50768-50775, 2002.

Pedram A., Razandi M. and Levin E.R. Nature of functional
the plasma membrane. Mol. Endocrinol. 20: 1996-2009, 2006.

Peng B., Lu B., Leygue E. and Murphy L.C. Putative functi
human estrogen receptor-1 isoforms. J. Mol. Endocrinol. 30: 11-19, 2003.

Perry R.R., Kang Y. and Greaves B. Effects of tamoxifen on
of estrogen-dependent and independent human breast cancer cells. Ann. Surg. Oncol. 2: 238-245, 1995.

Petersen O.W., Hoyer P.E. and van Deurs B. Frequency
estrogen receptor-positive cells in normal, nonlactating human
Cancer Res. 47: 574-575, 1987.

Pfeffer U., Fecarotta E., Castagnetta L. and Vidali G. Estrogen receptor variant
messenger RNA lacking exon-4 in estrogen-responsive human breast cancer
lines. Cancer Res. 53: 747-743, 1993.

Pfeffer U., Fecarotta E. and Vidali G. Coexpression of multi-
variant messenger RNAs in normal and neoplastic breast tissues and
cells. Cancer Res. 55: 215-218, 1995.

Pfeffer U. Estrogen receptor mRNA variants. Do they have
Ann. N.Y. Acad. Sci. 78: 403-413, 1996.

Pichon M.F., Pallud C., Brunet M. and Milgrom E. Relationship of presence
progesterone receptors to prognosis in early breast cancer. Cancer Res. 40: 3357-
3360, 1980.

Pike M.C., Krailo M.D., Henderson B.E., Casagrande J. Hormonal risk factors, breast tissue age, and the age in Nature 303 767-770, 1983.

Pink J.J., Jiang S.Y., Fritsch M. and Jordan V.C. MCF breast cancer cell line which contains a novel 80-kDa estrogen receptor protein. Cancer Res 55 2583-2590, 1995.

Pink J.J. and Jordan V.C. Models of estrogen receptor regu and antiestrogens in breast cancer cells. Cancer Res 56 2213-2230, 1996

Pink J.J., Bilimoria M.M., Assikis J. and Jordan V.C. Irr oestrogen receptor in breast cancer cells following prolonge deprivation. Br. J. Cancer 74 1227-1236, 1996

Pink J.J., Wu S.Q., Wolf D.M., Bilimoria M.M. and Jordan A. Novel 80 kDa human estrogen receptor containing a duplication of exons Nucleic Res 24 969-969, 1996

Pinto A.E., Saudade A. and Soares J. Short term significa cell proliferation in breast carcinoma: a multivariate analys in a series of 308 patients. Pathol 52 604-611, 1999.

Ponglikitmongkol M., Green S. and Chambon P. Genomic human oestrogen receptor. EMBO J. 7(11): 3385-3388, 1988.

Poola I., Koduri S., Chatra S. and Clarke R. Identification
spliced estrogen receptor mRNAs in breast cancer cell lines and tu
slice targeted primer. J. Steroid Biochem. Mol. Biol. 72 (4-5), 2000.

Poola I. and Speirs V. Expression of alternatively spliced
mRNAs is increased in breast cancer tissues. J. Steroid Biochem. Mol. Biol. 78
459-469, 2001.

Poola I., Abraham J. and Baldwin K. Identification of te
mRNAs in human ovary, breast, uterus and bone tissues: al
of estrogen receptor ² mRNA is distinct from the FEBS of estro
Lett. 516 (1-3), 1382, 2002a.

Poola I., Abraham J. and Leu A. Estrogen receptor ² splice variant mR
differentially altered during breast carcinogenesis. J. Steroid Biochem. Mol. B
82 (1-4), 1979, 2002b.

Poola I., Clarke R., DeWitty R. and Leffall L. Jr. Functio
receptor isoform profiles in the breast tumors of African
different from the profiles in breast tumors of Caucasian w
Cancer Cell 1.5
62, 2002.

Press M.F., Bernstein L., Thomas P.A., Zhou J.Y., Ma Y., H
Robinson R.A., Harris C.A., Slamon D.J., Phillips R.N.,
Wolman S.R and Flom-Keugh E. Ramplification characteriz

fluorescence in situ: poor prognostic indicator in breast cancer. J Clin Oncol 15(8): 2899-2904, 1997.

Ravdin P.M., Green S., Dorr T.M., McGuire W.L., Fabian C., Pu R.T., Rivkin S.E., Borst J.R., Abeloff M.D., Porter P.L., Osborne C.K., Hendricks C.B., Tormey D.C., Knight W.A., Ravdin R.G., Jones S.E., Mansour E.G., Ramsey J., Lippman M.E., Clark G.M., Allred D.C., Elledge R., Hilsenbeck S.G., Ciocca D.R., Wong F.L., Osborne K., Chamness G.C., Langone K.C., Lee A.V., Wiebe V.J., Bissell M.J., McCarty K.S., Jr., Yates J., Jr., Horwitz K.B., Wolfman W., Allegra J., Wittliff J., Fuqua S., Chamness G., Bock F., Desombre E.R., Jensen E.V., Brown A.M., Kenemore A., Wang H.Y., Shiurba R., Eisenberg P., Gorski J., Lippman M.E., Dickson R.B., Knabbe C., Bronzert D., Kasid A., Huff K., Kute T., Zava D., Haagensen D., Jr., Lawton P., Lykkesfeldt A., Sorensen B., Rasmussen B.B., Moller S., Rose C., Mouridsen H.T., Andersen J., Dowsett M., Houghton J., Kelly P., Angus B., Skilleter D., Gelber R.D., Rose C., Mouridsen H.T., Andersen J., Colombo N., Veronesi U., Rotmensz N., Bonadonna G., Borgen P.I., Wong G.Y., Lewis J., Lincoln T., Katrych D., Saigo P.E., Lee A.K., Kinne D., Strax P., Kim U., Matasar R., Adler I., Lesser M.L., Segaloff A., Dao T.L., Heuson J.C., Legros N., Paridaens R., Wildiers J., Bruning P.F., Hart A.A., Portengen H., Ravdin P.M., Clark G.M., Elledge R., Allred D.C., Hilsenbeck S., Ciocca D., Rosenquist C., Knight W.A., Ravdin R.G., Clemens M.R., Taylor C.W., Nicholson R.I., Gee J., Harper M.E., Hayes D.F., Trock B., Buzdar A., Hortobagyi G.N., Arteaga C.L., Prognostic significance progesterone receptor levels in estrogen receptor positive patients with metas breast cancer treated with tamoxifen: Results of a pros Oncology Group study. J Clin Oncol 10(8): 1282-1291, 1992.

Razandi M., Pedram A., Park S.T. and Levin E.R. Proximal events in plasma membrane estrogen signaling and interaction from activated estrogen receptor alpha and beta with cell communication and survival pathways. Mol Endocrinol 17(5): 879-895, 2003.

Razandi M., Alton G., Pedram A., Ghonshani S., Webb Identification of a structural determinant necessary for the of estrogen receptor alpha at the plasma membrane. J Biol Chem 278(3): 2071-2076, 2003b.

Read L.D., Greene G.L. and Katzenellenbogen B.S. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in cell lines by sex steroid hormones, their antagonists, and Mol Endocrinol 3(2): 295-304, 1989.

Reddel R.R., Murphy L.C. and Sutherland R.L. Factors affe T-47D human breast cancer cells. Cancer Res 44(1): 273-278, 1984.

Reddel R.R., Murphy L.C., Hall R.E and Sutherland R.L. D
human breast cell lines to the growth inhibitory effects of ta
Res 45 1521-1531, 1985.

Reddel R.E., Alexander I.E., Koga M., Shine J. and Suth
instability and the development of steroid hormone insensitiv
human breast cancer cell lines. Int. J. Cancer 41 343-347, 1988.

Reed W., Hannisdal E., Boehler P.J., Host H. and Mart
Prognostic value of p53-2 immunostaining is overrated for
with lymph node negative breast carcinoma. Cancer 88(4) 804-813, 2000.

Resnicoff M., Medrano E.E., Podhajcer O.L., Bravo A.I., B
Subpopulations of MCF7 cells separated by Percoll gradi
model to analyze the heterogeneity of hormone. Proc. Natl. Acad. Sci
USA 84 7297-7299, 1987.

Rich M.A., Furmanski P. and Brooks S.C. Prognostic value
determinations in patients with breast cancer. Cancer 42 1462-1468, 1978.

Ricketts D., Turnbull L., Barakat R., Rawson N.S., Gazet J.C
and Coombes R.C. Oestrogen and progesterone receptors in the
breast. Cancer Res 51 1817-1822, 1991.

Rilke F., Colnaghi M.I., Cascinelli N., Andreola S., Baldini
Porta G., Menard S., Pierotti M. A. and Testori A. Prognost
2/neu expression in breast cancer and its relationship to c
Int. J. Cancer 49(1): 44-49, 1991.

Robertson J.F., Howell A., Gorbunova V.A., Pienkowski T. and
Lichinitser M.R. Sensitivity to further endocrine therapy
progression-in first-line Breast Cancer Res. Treat. 92: 1617-4, 2005.

Rody A., Holtrich U., Solbach C., Kourtis K., von Minckwit
S., Gatje R., Karn T. and Kaufmann M. Methylation of estrogen recep
promoter correlates with expression in mammary carcinoma a
early indication marker in premalignant lesions. Cancer
Endocrine Relat. 12: 903-916, 2005.

Roger P., Sahla M.E., Makela S., Gustafsson J.A., Baldet
Decreased expression of estrogen receptor ² protein in pr
mammary tumors. Cancer Res. 61: 2537-2541, 2001.

Roos W., Fabbro D., Kung W., Costarger S.D. and Eppenberg
between hormone dependency and the regulation of epid
receptor by tumour promoters in human mammary carcinom
Proc. Natl. Acad. Sci. USA 83: 9991-9195, 1986.

Rose C., Thorpe S.M., Anderson K.W., Poulsen H.T., Blichert
Toft M. and Rasmussen B.B. Beneficial effect of tamoxif
cancer patients with high estrogen receptor values. Lancet 1:1618, 1985.

Rosen P.P., Lesser M.L., Arroyo C.D., Borgen P. and Norte
Immunohistochemical detection of HER-2/neu in patients with axillary lymph
negative breast cancer: a study of epidemiological risk factors
features, and prognosis. Cancer 75:1320-1326, 1995.

Rosenberg L.U., Magnusson C., Wendt S., Hall P. and Dickma
P.W. Menopausal hormone therapy and other breast cancer
to the risk of different histological subtypes of breast cancer
Breast Cancer Res. 8:R124, 2006.

Rowley J.D. Positive leukaemia, including chronic myelogenou
Clin. Haematol. 9:585, 1980.

Saez S., Pichon M.F., Chalbrix F., Pixo F. Estrone receptors and prog
early breast cancer. The experience of two centres. In Protein Ester and
progestin Bradin C.S., Milgrom E., Mauvais-Jarvis (eds). Raven Press,
York: pp-365-65, 1985.

Safe S. Transcriptional activation of genes by 17 beta-estrog
receptor-SP1 interactions. Vitam. Horm. 62:232-152, 2001.

Sager R. Genetic instability, suppression, and human cancer. In: Sager R. (ed.), Gene Regulation in the Expression of Malignancy. London Press, 1985.

Sainsbury J.R., Farndon J.R., Needham G.K., Malcolm A. Epidermal growth factor receptor status as predictor of early recurrence of death from breast cancer. Lancet 1(8554-7):1398-1402, 1987.

Saji S., Omoto Y., Shimizu C., Warner M., Hayashi Y., Horiguchi S., Hayashi S., Gustafsson J.A. Expression of estrogen receptor (²)cx in ER(+) breast cancer: specific correlation with receptor. Cancer Res. 62:4844-4853, 2002a.

Saji S., Omoto Y., Shimizu C., Watanabe T., Hayashi S.N., Gustafsson J.A. and Toi M. Clinical impact of estrogen receptor ²cx breast cancer. Breast Cancer 9:203-207, 2002.

Sartorius C. A., Melville M.Y., Hovland A.R., Tung L., Takimoto G.S., Horwitz K.B. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-type receptor. Endocrinol. 134-1360, 1994.

Sartorius C.A., Groshong S.D., Miller L.A., Powell L.T., Tarwater P.M., Horwitz K.B. New T47D breast cancer cell lines for the independent study

B- and -Receptors: only antiprocupsidene receptors are switched t
transcriptional agonists by cAMP. Cancer Res. 3868-3877, 1994

Schetter A.J., Leung S.Y., Sohn J.J., Zanetti K.A., Bowma
Yuen S.T., Chan T.L., Kwong D.L., Cualin K.G., Liu Croce C.M.
Harris C.M. MicroRNA expression profiles associated with
therapeutic outcome in colon adenocarcinoma. JAMA 299: 425-436, 2008.

Schiff R., Massarweh S., Shou J. and Osborne C.K. Brea
resistance: how growth factor signalling and estrogen rec
modulate response. Clinical Cancer Research 9: 447-454, 2003.

Sedlacek S.M. and Horwitz K.B. The role of progestins
receptors in the treatment of breast cancer. Steroids 44: 467-484, 1984.

Sempere L.F., Christensen M., Silahtaroglu A., Bak M., He
Wells W., Kauppinen S. and Cole C.N. Altered MicroRNA expression conf
specific epithelial cell subpopulations in breast cancer. Cancer Res. 67: 11612-11620, 2007.

Sengupta S. and Jordan V.C. Selective estrogen modulators as an ar
mechanisms of efficiency and resistance. Adv. Exp. Med. Biol. 630: 202-219, 2008.

Shackney S.E., Smith C.A., Miller B.W., Burchell H.R., Girhost D.R., M
Ketterer D.M. and Pollice A.A. Model for the genetic evo
tumors. Cancer Res. 49: 3344-3354, 1989.

Shaw J.A., Udokang K., Mosquera J.M., Chauhan H., Jones
Oestrogen receptors ± and ² differ in the normal breast and brea
carcinomas. J. Pathol. 198: 450-457, 2002.

Shek L.L. and Godolphin W. Survival with breast cancer:
estrogen receptor quantity. Cancer Clin. Oncol. 25: 2425-2850, 1989.

Sherman M.R., Corval P.L., Ley B.W. and Mayesterone binding com
of chick oviduct. J. Biol. Chem. 245: 6085-6096, 1972.

Singh L., Wilson A.J., Blaustein M.W., Bauer W.F., Birch I.H., Jackson I.M
C. and Palmer M.K. The relationship between histological grad
receptor status, events and survival at 8 years in the NATO (
Cancer. 57: 1614-1621, 1988.

Slater T.F., Sawyer B. and Strauli U. Studies on succinate-
systems. III. Points of coupling of four different Biochem. Biophys. Un
Acta. 77: 383, 1963.

Slattery M.L., Potter J.D., Curtin K.N., Edwards K.S., Schaffer
D. and Samowitz W.S. Estrogens reduce and withdrawal o

risk of microsatellite-positive colon cancer. Research 61: 126-130, 2001

Smith C.L. and O Malley B.W. Coregulator function: A key t
specificity of selective receptor modulators. Endocrinology 25: 4-7, 2004.

Soto A.M. and Sonnenschein C. The role of estrogens on
human breast tumor-cell stimulation. J. Steroid Biochem. 23: 8-9, 1985.

Sotoca A.M., van Berg H., Vervoort J., van der Saag P., Sotr
J-A., Rietjens I. and Murk A.J. Influence of cellular ER±/E
agonist induced proliferation of human T47D breast cancer
303-311, 2008.

Soule H.D., Vazquez J., Long A., Abert S. and Brennan M. A hur
a pleural effusion derived from a breast cancer. J. Natl. Cancer Inst. 51: 1409-1413, 1973.

Speirs V., Parkes A.T., Kerin M.J., Walton D.S., Carleton P
S.L. Expression of estrogen receptor and other prognostic factors in h
breast cancer. Cancer Res. 59: 525-528, 1999.

Spyratos F. DNA content and cell cycle analysis by flow
samples: application in breast cancer. Biol. Cell 78: 69-72, 1993.

Stål O., Dufmats M., Hatschek T., Carstensen J., Klintenb
Skoog L., Sullivan S., Wingren S. an-phase Nordenskjöld B. aS
prognostic factor in stage I breast cancer. J. Clin. Oncol. 11: 707-717, 1993.

Stendahl M., Rydén L., Nordenskjöld B., Jönsson P.E., Landberg G. and Jir
K. High progesterone receptor expression correlates to t
tamoxifen in premenopausal breast cancer. Clin. Cancer Res. 12: 4610-4
4618, 2006.

Ström A., Hartman J., Foster J.S., Kietz S., Wimalasena J. an
Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of
breast cancer cells. Proc. Natl. Acad. Sci. U S A 101: 1566-1571, 2004.

Suzuki T., Miki Y., Nakamura J., Moriya T., Ito K., Ohuchi N. and Sasa
steroid-producing enzymes in human breast cancer. Endocr. Relat. Cancer
701-720, 2005.

Suzuki T., Miki Y., Moriya T., Akahira J., Hirakawa H., Ohu
situ production of sex steroids in breast cancer. Mol. Cell. Endocrinol.
121-127, 2007.

Szyczak J., Milewicz A., Thijssen J.H.H., Blankenstein M.
Concentration of sex steroids in adipose tissue after men
319-321, 1998.

Takahashi K., Ozaki T., Kurioka H., Manabe A., Kar
Miyazaki K. Safety and efficacy of oestriol for symptoms
induced menopause. Hum. Rep. 15: 1021-1036, 2000.

Tartter P.I., Papatestas A.E., Mulvihill M.N., Mesnick G. and Aufses
A.H. Cholesterol and obesity as prognostic factors in breas
Cancer 47: 222-222, 1981.

Taylor S.E., Hirsch P.L. and Martin F.L. Oestrogen receptor
in the pathogenesis of breast cancer. Cancer 128: 133-148, 2010.

Thiebaud D. and Secrest R.J. Selective estrogen receptor m
of action and clinical experience. Recurs on Fertil Dev. 13: 331-336, 2001.

Thorpe S.M., Rose C., Rasmussen B.B., Mouridsen H.T., Ba
Prognostic value of steroid hormone receptor multivariate analysis
systemically untreated patients with node negative primary
Cancer Res. 47: 612-6133, 1987.

Toi M., Akihko O., Yamada H. and Toge T. Epidermal Gro
expression as a prognostic indicator. Eur. J. Cancer 27: 977-980, 1991.

Toikkanen S., Joensuu H. and Klemi P. The prognostic si
DNA content in invasive breast cancer from follow-up. Br. J.
Cancer 60: 697-700, 1989.

Tremblay G., Tremblay A., Copeland N., Gilbert D., Jenki
Giguere V. Cloning, chromosomal localization and funct
murine estrogen receptor. Mol. Endocrinol. 11: 353-365, 1997.

Twentyman P. and Luscombe M. A study of some variables in a
(MTT) based assay for cell growth and chemosensitivity. Br. J. Cancer 56: 279-
285, 1987.

Umayahara Y., Kawamori R., Watada H., Imano E., Iwama
Yamasaki Y., Kajimoto Y. and Kamata T. Estrogen regulation of th
growth factor I gene transcription in vascular. Chem. Biol. 1: 269-
1643-1644, 1994.

Utsumi T., Harada N., Maruta M. and Takagi Y. Presence o
transcripts of aromatase gene in human breast cancer. J. Clin. Endocrinol. Meta
81: 2342-2349, 1996.

van Landegham A.A.J., Portman J. and Nabauurs M. Endog
and subcellular distribution of estrogens in normal and m
tissue. Cancer Res. 45: 2900-2906, 1985

Van Netten J.P., Armstrong J.G., Cahill G., Goodchild N.L., Thornton I
Brigden M.L., Coy P. and Fletcher C. Estrogen receptor distribution
peripheral, intermediate and central regions of Cancer Jour. Clin. canc
Oncol. 14 1885-1889, 1988.

Verghese E.T., Hanby A.M., Speirs V. and Hughes T.A.
microRNAs and breast cancer where we now? Path. 215 2-421,
2008.

Vergote I., Robertson J.F.R., Kleeberg U.K., Bruhn M., Giacobbo
Postmenopausal women who progress on fulvestrant (Faslo
to further endocrine treatment. Res. Treat. 79 2021, 2003.

Vladusic E.A., Hornby A.E., Guerra-Vladusic F.K. and Lupu R. Expres
estrogen receptor messenger RNA variant in breast cancer. Cancer Research
58 2-2014, 1998.

Vogel V.G., Constantino J.P., Wickerham D.L., Cronin W.M.
J.N., Bevers T.B., Fehrenbacher L., Pajon E.R., Jr., Wade J.L., Robidoux A.,
Margolese R.G., James J., Lippman S.M., Runowicz C.D., Ganz
McCaskill-Stevens W., Ford L.G., Jordan V.C. and Wolfmark
tamoxifen vs raloxifene on the risk of developing invasive
disease outcomes: the NSAB Study of Tamoxifen and Raloxifene (STA
Trial. JAMA 295 2-27741, 2006.

Wada-Hiraike O., Imamov O., Hiraike H., Hultenby K., Schw
Warner M. and Gustafsson J. A. Role of estrogen receptor ² in colonic
PNAS 103 2959-2964, 2006

Wakeling A.E., Dukes M. and Bowler J. A potent specific p
clinical potential. Cancer Res. 51: 3867-3873, 1991.

Wakeling A.E. Similarities and distinctions in the mode of action of diff
classes of antiestrogens. Endocrinol. Relat. 7: 1-28, 2000.

Walker A.R., Adam F.I. and Walker B.F. Breast cancer in b
changing situation. J. R. Soc. Promot. Health 2: 85-104, 2010.

Walter P., Green S., Greene G., Krust A., Bornert J.M., Staub
Jensen E., Scrace G., Waterfield P. M. and Chambon P. Cloning of the human
estrogen receptor cDNA. Proc. Natl. Acad. Sci. 78: 8793-8797, 1985.

Wang Y. and Miksicek R.J. Identification of a dominant negative form of
human estrogen receptor. Mol. Endocrinol. 5: 1707-1715, 1991.

Ward H.W.C. Anti-oestrogen therapy for breast cancer: a trial of two dose leve
Br. Med. J. 1: 1-14, 1973.

Warner M.R. Effect of perinatal oestrogen on the pre-pubertal mammary
mammary bulbar formation. J. Endocrinol. 77: 1-10, 1978.

Watanabe T., Inoue s., Ogawa S., Ishii Y., Hiroi H., Ike
Muramatsu M. Agonistic effect of tamoxifen is dependen
promote context, and estrogen receptor subtype: functional
estrogen receptors Biochem. Biophys. Res. Comm., 236 1-4045, 1997.

Webb P., Lopez G.N., Uht R.M. and Kushner P.J. Tamoxif
estrogen receptor/AP-1 pathway: potential origin for the cell-type
effects of antiestrogens. Mol. Endocrinol. 9: 1445-1456, 1995.

Wells A. The epidermal growth factor receptor (EGFR) cancer
therapy. Signal 1: 411, 2000.

Westley B., May F.E.B., Brown A.C., Krust A. and Chambon P. Effects of
antiestrogens on the estrogen-regulated pS2 RNA 52kDa and 160kDa p
MCF-7 cells and two tamoxifen resistant sublines. J. Biol. Chem. 1: 0-30
10035, 1984.

Wienand U., Schwarz Z. and Feix G. Electrophoric acids
gels adapted for subsequent biological tests: Application
from maize endosperm. Int. 31-923, 1997

Wiseman L.R. and McTavish D. Formestane. A review of it
and pharmacokinetic properties and therapeutic potential in the
breast cancer and prostatic cancer. Drugs 45: 684, 1993.

Wittliff J.L. Steroid receptors in breast cancer. Cancer 53: 630-643, 1984.

Wolf D.M., Langan S.M., Parker S.M., Mc Cad Jordan V.C. Investigation of the mechanism of tamoxifen stimulated bre non-isomerizable analogues of tamoxifen. J. Nat. Cancer Inst. 85: 806-812, 1993.

Wolf D.M. and Jordan V.C. Characterization of tamoxifen-MCF-7 tumor variants grown in athymic mice. Breast Cancer Res. 31: 1127-1, 1994.

Woodburn J.R. The epidermal growth factor receptor and i therapy. Pharmacol. Ther. 82: 241-250, 1999.

Xing W. and Archer T.K. Stimulatory factors mediate estroge activation of the cathepsin D promoter. Mol. Endocrinol. 12: 1310-1321, 1998.

Yap O.W.S., Bhat G., Liu L. and Tollefsbol T.O. Epigenetic estrogen receptor ² gene in epithelial ovarian cancer. Res. cell 139: 144, 2009

Yamamoto K.R. Steroid receptor regulated transcription of s gene network. Annu. Rev. Genet. 19: 209-252, 1985

Zaucha R., Sekiel K. and Jassem J. Long Survival of a patie
with primarily chemoresistant metastatic breast canc
medroxyprogesterone acetate. Breast 13: 124, 2004.

Zhang Q.X., Hilsenbeck S.G., Fuqua S.A. and Borg A. Multi
the estrogen receptor are present in individual human brea
Biochem. Mol. Biol. 59: 251-260, 1996.

Zhao C., Lam E.W., Sunters A., Enmark E., De Bella M.
Gustafsson J.A. and Dahlman K. Expression of estrogen receptor
isoforms in normal breast epithelial cells and breast c
methylation. Oncogene 22: 7670-7606, 2003.

Zwijsen R.M., Wientjens E., Klompmaker R.J., Bernards R.
Michalides R.J. Independent activation of estrogen receptor by cy
Cell 88: 405-415, 1997.